Integrating Cellvizio® into TaeWoong’s portfolio of therapeutic devices to create the first fully integrated “imaging-to-therapy” solution for...
NMPA approval obtained following a 3-year certification process Mauna Kea is now evaluating options to commercialize Cellvizio Gen 3 in China...
70% debt write-off, from €40M to €12M Remaining debt to be repaid over 10 years, with 90% between the end of 2029 and the end of 2035 ...
Safeguard plan approved by judgment of the Paris Commercial Court on November 12, 2025 Launch of a reserved capital increase in the form of...
New equity financing would provide the Company sufficient financial visibility to execute its strategic plan and achieve profitability The...
U.S. sales surge +31% at constant exchange rates, with continued acceleration over the year Commercial momentum highlighted by a doubling of U.S....
Capital increase of €5m to €8m through a private placement planned for the first half of November via the issuance of shares with attached warrants...
A large majority of creditors and shareholders have voted in favor of the draft safeguard plan This plan includes a 70% reduction in debt,...
32% Reduction in H1 2025 Current Operating Loss excluding [Non-cash] Share-based Payments Improvement Reflects Strict Expense Control...
Reduction of the Company's debt from €40 million to €12 million, spread over 10 years Capital increase of at least €5 million post-plan adoption,...
Paris, Boston and Sydney, September 18, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT) and Endotherapeutics, today...
Shareholders, holders of securities giving access to the capital, and creditors of Mauna Kea Technologies convened into classes of affected parties...
